This investigation was undertaken in view of the interest lately aroused in the association of plasma lipids with atherosclerosis. Observations on the antilipemic and anticoagulant activities in man of sodium polyethylene sulfonate, a new drug with heparin-like properties, are presented. Alteration of the serum lipoprotein patterns of these patients observed during the course of the drug administration is also described. S ODIUM polyethylene sulfonate (U-6812),* a new heparin-like preparation, is a polymerized sodium salt of ethylenesulfonic acid. It is a white amorphous powder and highly soluble in water. In sterile water solution the material is stable at room temperature for 6 OP more months.
This investigation was undertaken in view of the interest lately aroused in the association of plasma lipids with atherosclerosis. Observations on the antilipemic and anticoagulant activities in man of sodium polyethylene sulfonate, a new drug with heparin-like properties, are presented. Alteration of the serum lipoprotein patterns of these patients observed during the course of the drug administration is also described. S ODIUM polyethylene sulfonate (U-6812),* a new heparin-like preparation, is a polymerized sodium salt of ethylenesulfonic acid. It is a white amorphous powder and highly soluble in water. In sterile water solution the material is stable at room temperature for 6 OP more months. 1 Coleman and his associates found that in laboratory animals the drug displays a more potent antilipemic activity and a much weaker anticoagulant activity than a same dose of heparin. Dogs tolerated daily doses up to 2 mg./Kg. for periods of 2 or more months without showing adverse effects during life. However, some of the animals showed a mild to moderate degree of intestinal irritation when examined at autopsy. Larger amounts produced anorexia, inactivity, diarrhea, gastrointestinal bleeding and death. The picture was similar to that observed in animals given toxic doses of heparin. Protamine sulfate abolishes the excessive anticoagulant effect of U-6812 in much the same manner as it acts against heparin. This work was done during the tenure of Dr. Kuo of an Established Investigatorship of the American Heart Association.
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METHODS
The clearing factor and anticoagulant activity of a single intramuscular injection of 1 to 1.5 mg./ Kg. of U-6812 was compared with that of heparin in 12 patients. Injections were given to the patients during the fasting state, and blood samples were taken 2 and 4 hours afterwards for determination of clearing factor activity by a modified technic of Brown, Boyle and Anfinson.* A modified Lee-White blood coagulation time technie was used to measure the anticoagulant activity. A coagulogram which included clotting time, prothrombin consumption, clot retraction, platelet count, recaleifleation time, one stage prothrombin concentration, plasma accelerator globulin concentration, and heparin titration*' * was made in most of the patients during the course of administration.
In vivo antilipemic tests were performed on one of us (P. K.) and on a patient with idiopathic hyperlipemia (A. J.). A dose of 0.2 mg./ Kg. was given intramuscularly with the ingestion of the first fatty meal. A second fatty meal was given to the subject 4 hours after the first one. Blood samples were drawn at intervals of up to 10 hours after the first meal. The plasma optical density of each specimen was determined with a Coleman Junior spectrophotometer. To determine the effect of U-6812 on serum lipids and lipoproteins, 10 patients who had been kept on a constant fat intake from 8 months to 3 years and have had frequent blood lipid studies during this period were admitted to the hospital for study. Fasting blood samples were drawn for serum cholesterol, phospholipids, total esterifled acids, lipoprotein pattern (paper electrophoretic technic), coagulogram, and clearing factor activity determinations at various times during the period of U-6812 administration. Each patient received an intramuscular injection of 1 mg./Kg. of the drug every S hours. The methods of Abell, Levy, Brodie and Paper electrophoresis of serum lipoproteins was performed according to the technic of Grossmann and Hannig.* The stained lipoprotein pattern was plotted from readings obtained by scanning with a densitometer. The areas under the a and y3-lipoprotein curves were measured by a planimeter and the relative percentages of the two lipid zones were calculated.
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RESULTS

Antilipemic
Test. Two subjects were given 0.2 mg./Kg. of U-6812 intramuscularly with the ingestion of a standard fatty meal. The subjects took a second identical meal 4 hours after the first one, but without another injection of the drug. Blood samples were drawn at intervals, and plasma lactescence of each of the specimens was measured. The time-density curves of the plasma turbidity of these two subjects are shown in figure 1. In the case of P. K., his plasma lactescence continued to rise following the first meal and reached a peak 6 hours after the first, and 2 hours after the second meal, respectively. His plasma lactescence curve returned to the fasting level 10 hours after the test had begun. plasma lectescence curve shows a two-stage rise following the test meals, and remains elevated at the end of the test. It is apparent that, at least under the conditions used, a single dosage of 0.2 mg./Kg. of the drug did not prevent postabsorptive lipemia in these 2 subjects. Anticoagulant Activity. Table 1 summarizes the observations made on the comparative study of anticoagulant activity of U-6812 and heparin. The top of table 1 shows the studies made on 6 patients. Each of them, in the fasting state, received intramuscularly a 1 mg./Kg. dose of U-6812, and 2 to 4 days later a similar dose of heparin. Blood coagulation times were determined 2 and 4 hours after each injection. The data show marked individual variations in the coagulation time readings following both U-6812 and heparin administrations among the patients studied, and that U-6812 had a somewhat less potent anticoagulant effect than an equivalent amount of heparin when administered to the same subject. Similar results were obtained from 6 other patients who received 1.5 mg./Kg. test doses of U-6812 and later of heparin (table 1, bottom).
Clearing Factor Activity. Blood samples from these 12 patients, 2 and 4 hours after an intramuscular injection of heparin and U-6812, were also tested for clearing factor activity. The plasma from each specimen was incubated with a synthetic fat emulsion. The amount of optical clearing in the emulsion produced by the plasma was measured ( patients who received 1 mg./Kg. dose heparin and later of U-6812; the bottom sho a similar study of 6 patients who received '. mg./Kg. doses of these two drugs at differ* times. As indicated, the plasma cleari activities in both groups show marked indiv ual variations following either heparin U-6812 injection. A comparative study show that there was no apparent difference in 1 fat emulsion clearing activities of the t ugs, under the conditions used in the study.
Changes in Blood Lipids Following V-6812
Iministration.
The blood lipid levels of patients were determined at intervals be-•e and after the administration of 1 mg./Kg. 5812 every 8 hours for 14 to 56 day periods. ese patients were kept on a constant low intake between 20 to 30 Gm./day during j study. Table 3 presents the mean blood id values before and after U-6812 adminration in these patients for comparison, mpared with the control periods, the mean al serum cholesterol of most of these pants showed a tendency to decrease, while iir mean serum phospholipid values tended increase with U-6812 injection. A relative rease in the mean a-lipoproteins with a responding decrease in the mean /3 fraction s observed in all 10 patients. The total um esterified fatty acid levels, however, re not significantly altered by the drug. Ln example of the effect of U-6812 on serum ids of patients who received 2 courses of >812 injections is shown in figure 2 and 3 . S.). Dosage of the drug used was mg./Kg. every 12 hours. The serum >spholipid and cholesterol differential in se patients began to increase 3 to 4 days er the injections were started, and reached maximum in 3 weeks' time ( fig. 2) . The rease in the phospholipid-cholesterol difential was maintained for some time after nination of U-6812 administration. Mgure 3 shows the relative concentrations Flo. 3. Serum a and ^3-lipoprotein levels of H. S. observed during the same study outlined in figure 2.
of serum a and y8-lipoproteins of the patient obtained during drug-administration and drug-free periods. A relative increase in the a-lipoproteins with a corresponding decrease in the /}-lipoproteins was observed following each period of U-6812 administration.
Effects on the Coagulogram. Coagulation tests revealed in all patients studied a prolongation of the one stage prothrombin test (33 to 40 per cent). In all instances, this was due to a marked lowering of the plasma accelerator globulin component (0 to 20 per cent). Stable factor deficiency was ruled out by lack of correction of the prothrombin time by stored serum. Poor consumption of prothrombin was noted in all patients. I t was 182 KUO, HOPKINS AND WUEZBL marked (11 to 14 sec.) in all but one. An increased amount of protamine sulfate was found to be needed to neutralize heparin in all but one case in the protamine-heparin titration test. No change was found in the platelet count, clot retraction or recaleification time in any of the patients studied.
Toxicity. In addition to the effect in all the subjects on plasma Ac-globulin, one patient (J. A.) developed epistaxis and watery diarrhea accompanied by abdominal cramps in the fourth week of U-6812 administration, while receiving U-6812 1 mg./Kg. every 8 hours. His blood clotting time was a little over 3 times its control value. No fresh or digested blood was noted grossly in his stools. The symptoms cleared promptly after the drug was stopped. This patient suffered from a recurrence of symptoms 3 weeks after the resumption of a second course of U-6812 injections. The majority of patients complained of considerable local irritation after two weeks of repeated intramuscular injections.
DISCUSSION
The sodium salt of polyethylene sulfonic acid with moderate degrees of polymerization (U-6812) has been found to cause in human subjects a prolongation of the whole blood clotting-time similar to, but in a somewhat lesser degree, than an equivalent dose of heparin. Although, in the preliminary stages of the development, Coleman and his associates estimated that in laboratory animals U-6812 possesses about one-half to two-thirds of the anticoagulant activity of heparin. 1 The poor prothrombin consumption observed in these patients with U-6812 administration was due in part to the lowered plasma Ac-globulin level 9 and in part to the heparin-like effect of the drug. To our knowledge, similar depression of plasma Ac-globulin has not been observed following the administration of heparin, dextran sulfate and other similar preparations with heparinoid activity. 10 -" U-6812 probably suppresses plasma Ac-globulin either by interfering with its formation in the liver or by inactivating or destroying it in the circulating blood.
An increase in the clearing factor activity was demonstrated in vitro in all of our patients 2 and 4 hours after an injection of U-6812, but the drug in a single 0.2 mg./Kg. dose failed to prevent postabsorptive lipemia in one of us and in a hyperlipemic patient. Iu 10 other patients, prolonged administration of moderately large doses of the drug did not produce a significant lowering of their serum triglycerides from their respective control levels. These observations would indicate that antilipemic activity of U-6812 in man is at least quantitatively different from that of laboratory animals. 1 Prolonged administration of U-6812 in these patients tends to suppress serum cholesterol and to elevate the serum phospholipids resulting in an increase in phospholipid-cholesterol differential. These changes in blood lipids appear to coincide with the relative increase in serum a-lipoprotein fraction and a relative decrease in the /3 fraction as studied by paper electrophoresis technic. It is interesting to note that the effect of U-6812 on the serum lipoproteins in this series of patients is generally similar to that of estrogens in altering the abnormal serum lipid patterns in experimental and clinical atherosclerosis as reported by Barr, Steiner, Katz, Robinson and their associates. ia ' 1B Unlike estrogens, no feminizing properties were observed in our patients with U-6812 administration. The question whether the changes observed in the serum lipoprotein pattern following U-6812 administration are due to a basic alteration of lipoprotein production in the liver or due to a change in the chemicophysical nature and electrophoretie mobility of some of the /3-lipoprotein molecules, cannot be answered at this time.
It would be of interest to determine whether the apparent increase in serum a-lipoproteins with a concomitant decrease in the /3 fractions: (1) can be maintained by a relatively small and nontoxic dose of the drug for a prolonged period of time, and (2) can exert a beneficial effect upon experimental and human atherosclerosis.
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SUMMARY
An intramuscular injection of 1 to 1.5 mg./Kg. of sodium polyethylene sulfonate (U-6812) prolonged the blood clotting-time in variable degrees in 12 patients. However, in most of them its anticoagulant activity was somewhat less than that of an equivalent dose of heparin. Other changes in the coagulogram of patients receiving U-6812 injections were low prothrombin consumption, low prothrombin concentration, and very low plasma Ac-globulin content.
An increase in clearing factor activity was demonstrated in the plasma of all patients following U-6812 administration. In these patients the lipemia clearing activity of the drug was found to be similar to equivalent doses of heparin injections. No significant change in the fasting serum triglycerides was observed in 10 patients who received 1 mg./Kg. of U-6812 every 8 hours for 14 to 56 days.
U-6812 administration produced a relative increase in a-lipoproteins and a corresponding decrease in the /3-lipoproteins in all patients studied. At the same time, their serum cholesterol tended to decrease and their serum phospholipids to increase.
One patient in this series developed 2 attacks of epistaxis and diarrhea with abdominal pain following each of the 2 courses of U-6812 administration. His symptoms disappeared when injections were stopped. Local irritation appeared in the majority of patients after repeated injections for 2 to 3 weeks.
SUMMARIO IN INTERLINGUA
Un injection intramuscular de 1 a 1,5 mg/kg de natrium polyethyleno-sulfonate (U-6812) prolongava le tempore del coagulation de sanguine in 12 patientes a varie grados. Tamen, in le majoritate del casos, le activitate anticoagulante de U-6812 esseva levemente inferior a illo de heparina in dosage equivalente. Alterationes additional del coagulogramma notate in patientes recipiente injectiones de U-6812 esseva basse consumption de prothrombina, basse concentration de prothrombina, e bassissime contento de globulina Ac in le plasma.
Un augmento del activitate de factor de clearing esseva demonstrate in le plasma de omne patientes a qui U-6812 habeva essite administrate. In iste patientes le activitate del clearing de lipemia manifestate per le droga se monstrava simile a illo de injectiones de equivalente doses de heparina. Nulle significative alterationes del triglyceridos serai esseva observate in 10 patientes qui recipeva 1 mg/kg de U-6812 omne 8 horas durante 14 a 56 dies.
Le administration de U-6812 produceva in omne patientes studiate un augmento relative del lipoproteinas alpha e un reduction correspondente del lipoproteinas beta. Al mesme tempore, le cholesterol serai de iste patientes manifestava un tendentia a diminuer se e le phospholipidos a augmentar se.
Un patiente in iste serie disveloppava 2 attaccos de epistaxe e diarrhea con dolores abdominal post ambes de 2 cursos de U-6812. Le symptomas dispareva quando le injectiones esseva interrumpite. Irritation local appareva in le majoritate del patientes post repetite injectiones durante 2 a 3 septimanas.
